Tag: Vadastuximab talirine
ADCs – The Dawn of a New Era?
Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.
Phase III CASCADE Clinical Trial of Vadastuximab Talirine in Frontline Acute...
Earlier today, Seattle Genetics confirmed that it discontinued the phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia...
U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine
The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...
Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...
Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...
Vadastuximab Talirine is Well-Tolerated with Rapid, High Remission Rates for AML...
Highlighted in three oral data presentations during the 58th annual meeting of the American Society of Hematology, being held in San Diego, CA, December...
Study Shows 76% Objective Response Rate in Newly Diagnosed Acute Myeloid...
Phase I clinical data from a study evaluating vadastuximab talirine, also known as SGN-CD33A or 33A in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in...
Pivotal Trial with Vadastuximab Talirine Initiated for Treatment of Patients with...
A phase III study called CASCADE, designed to evaluate Seattle Genetics' vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) or decitabine (Dacogen) has...
Vadastuximab Talirine (SGN-CD33A) Combination Therapy Evaluates Safety and Activity for Patients...
A new phase I/II clinical trial of vadastuximab talirine, also known as SGN-CD33A; 33A (Seattle Genetics), in combination with azacitidine (Vidaza®; Celgene Corporation) in patients with...
Vadastuximab Talirine Demonstrates Encouraging Anti-leukemic Activity in Acute Myeloid Leukemia
Several presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating vadastuximab...
